Related references
Note: Only part of the references are listed.Early-Phase 18F-Florbetapir and 18F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting
Cecilia Boccalini et al.
JOURNAL OF NUCLEAR MEDICINE (2023)
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
Camilla Caprioglio et al.
JAMA NETWORK OPEN (2023)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Willemijn J. Jansen et al.
JAMA NEUROLOGY (2022)
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
Matteo Cotta Ramusino et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6
Daniele Altomare et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
Naoya Hattori et al.
JOURNAL OF ALZHEIMERS DISEASE REPORTS (2020)
Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Antoine Leuzy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Gil D. Rabinovici et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project
Arno de Wilde et al.
ALZHEIMERS & DEMENTIA (2019)
AMYPAD Diagnostic and Patient Management Study: Rationale and design
Giovanni B. Frisoni et al.
ALZHEIMERS & DEMENTIA (2019)
Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET
Daniele Altomare et al.
ALZHEIMERS & DEMENTIA (2018)
Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort The ABIDE Project
Arno de Wilde et al.
JAMA NEUROLOGY (2018)
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Giovanni B. Frisoni et al.
LANCET NEUROLOGY (2017)
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Konstantinos Chiotis et al.
NEUROBIOLOGY OF AGING (2017)
Diagnostic impact of [18F] flutemetamol PET in early-onset dementia
Marissa D. Zwan et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Effectiveness of Florbetapir PET Imaging in Changing Patient Management
Michael J. Pontecorvo et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2017)
Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study
Marina Boccardi et al.
JAMA NEUROLOGY (2016)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Frank Jessen et al.
ALZHEIMERS & DEMENTIA (2014)
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort
Wiesje M. van der Flier et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
Impact of molecular imaging on the diagnostic process in a memory clinic
Rik Ossenkoppele et al.
ALZHEIMERS & DEMENTIA (2013)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
WE Klunk et al.
ANNALS OF NEUROLOGY (2004)
Potentially reversible conditions in 1000 consecutive memory clinic patients
A Hejl et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Share Paper
